Enhancing AAV Production: A Novel Transfection System for Cell and Gene Therapy Applications
On Demand Webinar
Enhancing AAV Production: A Novel Transfection System for Cell and Gene Therapy Applications
On Demand Webinar
Learn about the powerful capabilities of the TransIT®-AAViator Transfection System, a turnkey solution designed to significantly improve AAV transfection efficiency. Senior Process Developer at Affinia Therapeutics, Michael White, highlights the system’s scalability and ease of integration, making it ideal for gene therapy developers looking to optimize both upstream processes and overall cost-efficiency.
Michael shares Affinia Therapeutics’ experience with the TransIT-AAViator system, emphasizing its ability to reduce pDNA input requirements while maintaining robust titers across scales. Affinia achieved consistent production results, which led to more efficient manufacturing processes and substantial cost savings.
Discussion highlights include:
- Affinia’s approach comparing a next-gen transfection system to their current optimized platform (and the subsequent data)
- How Affinia compared TransIT-AAViator to other reagents and was able to outperform them straight out of the box
- Methodology used to achieve 3X higher titers and 70% full capsids
Ready to See if TransIT-AAViator is Right for You?
Schedule a meeting to discuss your needs and board your flight to higher titers and percent full capsids.
TransIT®-AAViator Transfection System
A new transfection system tailored specifically for maximal AAV production
THE EXPERTS
John Schiel, Ph.D.
Product Manager
Mirus Bio
Michael White, Ph.D.
Head of Process Development and Manufacturing Innovations
Affinia Therapeutics
Ready to See if TransIT-AAViator is Right for You?
Schedule a meeting to discuss your needs and board your flight to higher titers and percent full capsids.